Type 2 diabetes mellitus, diabetes Diabetes
Conditions
Interventions
None listed
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Caucasian (people will be excluded when having a >=50% racial African/Asian background); 2. Male or (postmenopausal; defined as 1 year after the last cycle) female; 3. Age between 40-75 years; 4. BMI: 25-35 kg/m2; 5. Pre-diabetes in one the following criteria: a. Impaired glucose tolerance: plasma glucose values >= 7.8 mmol/l and = 6.1 mmol/l and 3kg in the past 3 months); 7. Sedentary lifestyle (not more than 2 hours of vigorous exercise per week).
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: 1. Not meeting all inclusion criteria; 2. Type 2 diabetes (fasted blood glucose > 7 mmol/L or non-fasted > 11mmol/L); 3. Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk. 4. Alcohol consumption of >2 servings per day; 5. Currently smoking or having quit recently; 6. Low Hb (men: <8.6 mmol/L; women <7.4 mmol/L); 7. Subjects using anticoagulant medication (antiplatelet agents can be used, but other medications should be excluded); 8. Subjects who have participated in another biomedical study within the last 3 months that could interfere with the study results; 9. Subjects were involved in previous research that included PET/CT scanning; 10. Participants who do not want to be informed about unexpected medical findings; * 11. Participants who do not want that their treating physician to be informed; 12. Inability to participate and/or complete the required measurements; 13. Participation in organised or structured physical exercise (>2h per week); 14. Allergic or hypersensitive to iodine-containing contrast medium.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome parameter is insulin-stimulated 18F-FDG uptake in quadriceps muscle (expressed as Ki) as measured by means of [18F]-FDG PET and PVAT quantity and inflammation measured by CT angiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters are: - Skeletal muscle blood flow measured by contrast enhanced ultrasonography (CEUS); - Hepatic, myocardial, and whole-body glucose uptake rate (Ki) measured with PET-CT; - Skeletal muscle mitochondrial function measured by means of Oroboros in skeletal muscle biopsies; - Skeletal muscle intracellular insulin signalling pathways measured by Western blot in muscle biopsies. | — |
Countries
Netherlands
Contacts
Public ContactP.M.G. van Lier
Universiteit Maastricht
Outcome results
None listed